| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3980554 | Cancer Treatment Reviews | 2009 | 5 Pages |
Abstract
SummaryElderly patients with advanced non-small cell lung cancer (NSCLC) are at higher risk for adverse events related to treatment of their disease. Chemotherapeutic agents used alone or together may increase survival, while leading to increased treatment related morbidity. New targeted agents used to treat NSCLC have yet to show sufficient improvement in disease outcomes. This review will discuss the current management of elderly patients with advanced non-small cell lung cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Eric J. Avery, Anne Kessinger, Apar Kishor Ganti,